Developing protein arginine methyltransferase 1 (PRMT1) inhibitor TC-E-5003 as an antitumor drug using INEI drug delivery systems

Injectable implants with the ability to form in situ are one of the most promising carriers for the delivery of chemotherapeutic drugs to tumor sites. We have reported a novel injectable in situ-forming implant system composed of n-butyl-2-cyanoacrylate (NBCA), ethyl oleate, along with the sol-gel p...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Pengcheng, Tao, He, Yu, Liyang, Zhou, Lixiao, Zhu, Chenggang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170320/
https://www.ncbi.nlm.nih.gov/pubmed/32212935
http://dx.doi.org/10.1080/10717544.2020.1745327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170320/
https://www.ncbi.nlm.nih.gov/pubmed/32212935
http://dx.doi.org/10.1080/10717544.2020.1745327

Ejemplares similares